Sandoz Invests In Its Unique Antibiotics Offering
CEO Richard Saynor Outlines The Attraction Of Recently-Closed Deal With GSK
Executive Summary
In the wake of a major deal to acquire GlaxoSmithKline’s cephalosporins business, Sandoz CEO Richard Saynor has set out why the company’s unique position means that antibiotics are an important area for investments, in an exclusive interview with Generics Bulletin.
You may also be interested in...
European Industry Demands Action To Sustain Health Systems
Industry actors and outsiders alike discussed existing challenges for the EU healthcare system amid significant economic pressures, while calling for action to ensure a workable system for low-priced medicines.
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.
AMR Industry Alliance Publishes Manufacturing Standard
The AMR Industry Alliance has formalized its years-old Common Antibiotic Manufacturing Framework by publishing an antibiotic manufacturing standard, in what it terms a “groundbreaking step” in the drive for responsible manufacturing.